IBI 3002
Alternative Names: IBI-3002Latest Information Update: 15 Mar 2024
At a glance
- Originator Innovent Biologics
- Class Antiasthmatics; Bispecific antibodies
- Mechanism of Action Interleukin 4 inhibitors; Thymic stromal lymphopoietin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Asthma